TAp73和Beclin1在人骨肉瘤中表达及其临床意义

目的检测抑癌基因TAp73与自噬相关因子Beclin1在人骨肉瘤中的表达,探讨TAp73与肿瘤自噬的关系。方法采用免疫组织化学SP法检测TAp73、Beclin1在48例骨肉瘤患者的瘤体组织中的表达,结合患者的临床资料进行相关性分析。结果 TAp73在人骨肉瘤组织中的阳性率54.17%,Beclin1的阳性率为62.50%,TAp73阳性表达,其Beclin1表达程度较高(Z=-2.146,P=0.032)。在人骨肉瘤中TAp73的表达程度与Beclin1的表达程度呈正相关(r=0.470,P=0.001)。TAp73、Beclin1阳性表达的患者总体生存率优于阴性表达(80.8%vs 50.0%,P=0.000;80.0%vs 44.4%,P=0.001)。TAp73、Beclin1不同表达程度与患者的生存时间呈正相关(r=0.696,P=0.00;r=0.372,P=0.009)。结论在人骨肉瘤中TAp73可能与骨肉瘤中Beclin1依赖的肿瘤自噬活性上调有关。检测TAp73和Beclin1在人骨肉瘤中的表达水平有助于患者临床预后判断。

Expression of TAp73 and Beclin1 in human osteosarcoma and their clinical significance

Objective　To investigate the expression of TAp73 and Beclin1 in human osteosarcoma and their relationship.　Methods　The immunohistochemical SP method was used to detect the expressions of the TAp73 and Beclin1 proteins in 48 osteosarcoma patients’ tumor tissues, and the correlations of TAp73 and Beclin1 were analyzed with their clinical data.　Results　The positive rate of TAp73 was 54.17%, and the positive rate of Beclin1 was 60.42%. TAp73 positive expression, and the expression of Beclin1 were higher (Z=-2.146, P=0.032). The expression level of TAp73 was positively correlated with the expression of Beclin1 (P=0.001). The overall survival rate of patients with TAp73 and Beclin1 positive expression was better than that of negative expression (80.8% vs 50.0%, P=0.000, 80.0% vs 44.4%, P=0.001). The expression level of TAp73 and Beclin1 was positively correlated with the survival time of patients(r=0.696，P=0.00；r=0.372，P=0.009).　Conclusion　In human osteosarcoma, TAp73 may be related to the upregulation of Beclin1 dependent tumor autophagy activity. And to detect the expression of TAp73 and Beclin1 is helpful for the assessment of patients’ prognosis.